The Role of the Transforming Growth Factor-β Signaling Pathway in Gastrointestinal Cancers

Overview

Journal Biomolecules

Publisher MDPI

Specialties Biochemistry
Molecular Biology

Date 2023 Oct 28

PMID 37892233

Authors

Tasuku Matsuoka

Masakazu Yashiro

Affiliations

Soon will be listed here.

Abstract

Transforming growth factor-β (TGF-β) has attracted attention as a tumor suppressor because of its potent growth-suppressive effect on epithelial cells. Dysregulation of the TGF-β signaling pathway is considered to be one of the key factors in carcinogenesis, and genetic alterations affecting TGF-β signaling are extraordinarily common in cancers of the gastrointestinal system, such as hereditary nonpolyposis colon cancer and pancreatic cancer. Accumulating evidence suggests that TGF-β is produced from various types of cells in the tumor microenvironment and mediates extracellular matrix deposition, tumor angiogenesis, the formation of CAFs, and suppression of the anti-tumor immune reaction. It is also being considered as a factor that promotes the malignant transformation of cancer, particularly the invasion and metastasis of cancer cells, including epithelial-mesenchymal transition. Therefore, elucidating the role of TGF-β signaling in carcinogenesis, cancer invasion, and metastasis will provide novel basic insight for diagnosis and prognosis and the development of new molecularly targeted therapies for gastrointestinal cancers. In this review, we outline an overview of the complex mechanisms and functions of TGF-β signaling. Furthermore, we discuss the therapeutic potentials of targeting the TGF-β signaling pathway for gastrointestinal cancer treatment and discuss the remaining challenges and future perspectives on targeting this pathway.

Citing Articles

Peripheral immune signatures associated with the risk of hepatocarcinogenesis in cirrhotic Egyptian HCV patients before and after treatment with direct-acting antivirals.

El-Shenawy R, Moustafa R, Helmy N, El-Abd Y, Tabll A, Elesnawy Y Virol J. 2024; 21(1):293.

PMID: 39548562 PMC: 11566392. DOI: 10.1186/s12985-024-02551-3.

Molecular Mechanism for Malignant Progression of Gastric Cancer Within the Tumor Microenvironment.

Matsuoka T, Yashiro M Int J Mol Sci. 2024; 25(21).

PMID: 39519285 PMC: 11546171. DOI: 10.3390/ijms252111735.

Growth Factors and Their Application in the Therapy of Hereditary Neurodegenerative Diseases.

Issa S, Fayoud H, Shaimardanova A, Sufianov A, Sufianova G, Solovyeva V Biomedicines. 2024; 12(8).

PMID: 39200370 PMC: 11351319. DOI: 10.3390/biomedicines12081906.

Editorial: Clinical risk assessment and intervention of gastrointestinal tumors driven by big-data.

Zhang N, Wang W, Gao X, Gao F Front Med (Lausanne). 2024; 11:1379762.

PMID: 38476446 PMC: 10927941. DOI: 10.3389/fmed.2024.1379762.

Molecular Insight into Gastric Cancer Invasion-Current Status and Future Directions.

Matsuoka T, Yashiro M Cancers (Basel). 2024; 16(1).

PMID: 38201481 PMC: 10778111. DOI: 10.3390/cancers16010054.

References

Huang Y, Hu J, Chen F, Lecomte N, Basnet H, David C . ID1 Mediates Escape from TGFβ Tumor Suppression in Pancreatic Cancer. Cancer Discov. 2019; 10(1):142-157. PMC: 6954299. DOI: 10.1158/2159-8290.CD-19-0529. View

Mitra M, Lancaster K, Adedeji A, Palanisamy G, Dave R, Zhong F . A Potent Pan-TGFβ Neutralizing Monoclonal Antibody Elicits Cardiovascular Toxicity in Mice and Cynomolgus Monkeys. Toxicol Sci. 2020; 175(1):24-34. DOI: 10.1093/toxsci/kfaa024. View

Rahavi H, Alizadeh-Navaei R, Tehrani M . Efficacy of therapies targeting TGF-β in solid tumors: a systematic review and meta-analysis of clinical trials. Immunotherapy. 2023; 15(4):283-292. DOI: 10.2217/imt-2022-0079. View

Fu X, Chen X, Si Y, Yao Y, Jiang Z, Chen K . Long non-coding RNA NCK1-AS1 is overexpressed in esophageal squamous cell carcinoma and predicts survival. Bioengineered. 2022; 13(4):8302-8310. PMC: 9162014. DOI: 10.1080/21655979.2022.2038449. View

Derynck R, Zhang Y . Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003; 425(6958):577-84. DOI: 10.1038/nature02006. View

Hinshaw D, Shevde L . The Tumor Microenvironment Innately Modulates Cancer Progression. Cancer Res. 2019; 79(18):4557-4566. PMC: 6744958. DOI: 10.1158/0008-5472.CAN-18-3962. View

Zhang L, Song X, Chen X, Wang Q, Zheng X, Wu C . Circular RNA CircCACTIN Promotes Gastric Cancer Progression by Sponging MiR-331-3p and Regulating TGFBR1 Expression. Int J Biol Sci. 2019; 15(5):1091-1103. PMC: 6535790. DOI: 10.7150/ijbs.31533. View

Javanmard A, Dokanehiifard S, Bohlooli M, Soltani B . LOC646329 long non-coding RNA sponges miR-29b-1 and regulates TGFβ signaling in colorectal cancer. J Cancer Res Clin Oncol. 2020; 146(5):1205-1215. DOI: 10.1007/s00432-020-03145-6. View

Huang W, Tian X, Bi S, Zhang S, He T, Song L . The β-catenin/TCF-4-LINC01278-miR-1258-Smad2/3 axis promotes hepatocellular carcinoma metastasis. Oncogene. 2020; 39(23):4538-4550. PMC: 7269911. DOI: 10.1038/s41388-020-1307-3. View

10.

Riggins G, Kinzler K, Vogelstein B, Thiagalingam S . Frequency of Smad gene mutations in human cancers. Cancer Res. 1997; 57(13):2578-80. View

11.

Zou S, Li J, Zhou H, Frech C, Jiang X, Chu J . Mutational landscape of intrahepatic cholangiocarcinoma. Nat Commun. 2014; 5:5696. DOI: 10.1038/ncomms6696. View

12.

Huang Y, Lin P, Su W, Chan R, Chen P, Lin B . Association between Altered Oncogenic Signaling Pathways and Overall Survival of Patients with Metastatic Colorectal Cancer. Diagnostics (Basel). 2021; 11(12). PMC: 8700603. DOI: 10.3390/diagnostics11122308. View

13.

Hao Y, Baker D, Ten Dijke P . TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis. Int J Mol Sci. 2019; 20(11). PMC: 6600375. DOI: 10.3390/ijms20112767. View

14.

Li Q, Li M, Jiang Z, Hou Z, Liu W, Ma N . Downregulating Long Non-coding RNAs CTBP1-AS2 Inhibits Colorectal Cancer Development by Modulating the miR-93-5p/TGF-β/SMAD2/3 Pathway. Front Oncol. 2021; 11:626620. PMC: 8079788. DOI: 10.3389/fonc.2021.626620. View

15.

Bayat Z, Ghaemi Z, Behmanesh M, Soltani B . Hsa-miR-186-5p regulates TGFβ signaling pathway through expression suppression of SMAD6 and SMAD7 genes in colorectal cancer. Biol Chem. 2021; 402(4):469-480. DOI: 10.1515/hsz-2019-0407. View

16.

. Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2016; 20(1):1-19. PMC: 5215069. DOI: 10.1007/s10120-016-0622-4. View

17.

Katsuno Y, Derynck R . Epithelial plasticity, epithelial-mesenchymal transition, and the TGF-β family. Dev Cell. 2021; 56(6):726-746. DOI: 10.1016/j.devcel.2021.02.028. View

18.

Zhang X, Hu L, Yang Q, Qin W, Wang X, Xu C . CTHRC1 promotes liver metastasis by reshaping infiltrated macrophages through physical interactions with TGF-β receptors in colorectal cancer. Oncogene. 2021; 40(23):3959-3973. DOI: 10.1038/s41388-021-01827-0. View

19.

Gu S, Zaidi S, Hassan M, Mohammad T, Malta T, Noushmehr H . Mutated CEACAMs Disrupt Transforming Growth Factor Beta Signaling and Alter the Intestinal Microbiome to Promote Colorectal Carcinogenesis. Gastroenterology. 2019; 158(1):238-252. PMC: 7124154. DOI: 10.1053/j.gastro.2019.09.023. View

20.

Zhang L, Niu H, Ma J, Yuan B, Chen Y, Zhuang Y . The molecular mechanism of LncRNA34a-mediated regulation of bone metastasis in hepatocellular carcinoma. Mol Cancer. 2019; 18(1):120. PMC: 6659280. DOI: 10.1186/s12943-019-1044-9. View